---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-26-000069"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2026-06-09T11:30:05+00:00"
generated_at: "2026-06-09T11:36:20.558105+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Autolus files UK annual report highlighting AUCATZYL launch, pipeline progress, and EU sales delay

## Summary
- AUCATZYL launched in US (Jan 2025) and UK (Jan 2026) for r/r B-ALL; conditional EU approval but no 2026 sales planned.
- Obe-cel paediatric r/r B-ALL Phase 1b showed 95% ORR; Phase 2 enrollment expected complete H1 2027.
- Obe-cel advanced to Phase 2 pivotal trial (LUMINA) for lupus nephritis; Phase 1 MS trial dosing started Oct 2025.
- Manufacturing site Nucleus in Stevenage, UK; Cardinal Health 105 as US distribution partner.
- AGM scheduled for June 29, 2026; ADS holders of record May 27, 2026 eligible to vote.

## SEC filing metadata
- accession: 0001730463-26-000069
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2026-06-09T11:30:05+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/0001730463-26-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046326000069/autl-20260605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-26-000069
- JSON: https://secwatch.observer/filing/0001730463-26-000069.json
- Plain text: https://secwatch.observer/filing/0001730463-26-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.